BMS-690514, a reversible oral inhibitor of EGFR, HER-2 and −4, VEGFRs-1 to −3, showed antitumour activity in tumour xenograft models and in cell lines containing the EGFR T790M mutation, suggesting a role against erlotinib-resistant tumours [55]. The gene discussed is ERBB2; the disease is neoplasm.